Medtronic has reported $7.371bn global revenue for the first quarter (Q1) of the fiscal year 2023 (FY23), representing an 8% decrease as reported and 4% decrease on an organic basis.
This organic comparison excludes a $351m negative impact from foreign currency translation as well as $20m from the company’s recent acquisition of Intersect ENT.
Go deeper with GlobalData
For the quarter that ended on 29 July , the company’s GAAP net income was $929m, which grew by 22% from $763m reported in the same quarter of the previous fiscal year.
Diluted earnings per share (EPS) stood at $0.70, up by 25% from $0.56 the prior year.
Medtronic’s US revenue, representing 51% of total revenues, reported a decline of 8% on a reported basis and 9% on an organic basis, to $3.766bn.
See Also:
Non-US developed market revenues totalled $2.33bn, a decline by 10% on a reported basis and increase of 2% on an organic basis.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIn the fiscal first quarter of FY23, the company’s Cardiovascular portfolio revenue fell 6% as reported and 1% on organic basis, to $2.713bn.
This decline was due to a low-single-digit organic fall in Coronary & Peripheral Vascular (CPV) and Cardiac Rhythm & Heart Failure (CRHF), as well as flat year-over-year data in Structural Heart & Aortic (SHA).
The Medical Surgical portfolio reported $2bn revenue, down 14% as reported and 9% on an organic basis.
In the Neuroscience portfolio revenues were $2.115bn, down by 4% as reported and 2% organic.
This was due to mid-single-digit declines in Cranial & Spinal Technologies (CST) and Neuromodulation as well as mid-single-digit increases in Specialty Therapies.
Revenue in the Diabetes portfolio decreased by 5% as reported to $541m.
Medtronic chairman and CEO Geoff Martha said: “The company continues to execute in a challenging environment, delivering organic revenue above our guidance.
“As we look ahead, our supply chain is improving, we have several near-term pipeline catalysts approaching, and we are confident in our ability to accelerate growth.”
In July, the company entered into a strategic partnership agreement with CathWorks.
